Endocrine alterations during a detoxification treatment with carbamazepine in male alcoholics.
This study aimed to evaluate the prevalence and time-course of endocrine alterations in male alcohol addicts during a detoxification treatment and to examine a possible relation between endocrine alterations and depressive symptoms and overall mental distress. Blood samples were drawn in 54 male alcohol addicts on admission, at day 7 of treatment and at day 14 on discharge. Endocrine analysis was performed for cortisol, luteinizing hormone, prolactin, androgens, free testosterone and 17beta-estradiol. Psychometric measures (Beck's depression inventory and the symptom checklist-90-R) were taken on admission and on discharge and were correlated with endocrine measures. Cortisol plasma levels were substantially increased at the beginning of the detoxification, whereas all other endocrine parameters were within the normal range. Although subjects depicted mild to moderate levels of depressive symptoms and mental distress, there were no correlations with endocrine variables. Further analysis revealed a high variation in sex steroid levels with approximately 55% of participants showing initial (n = 19) or developing (n = 11) hypogonadal values during detoxification. In conclusion, chronic alcohol consumption induces disturbances of gonadal function which are reversible in the majority of cases. However, few patients develop a hypogonadal state during detoxification. Initially increased cortisol levels indicate a bodily stress response with the onset of alcohol withdrawal but are not related to mental disturbances.
Krüger
Tillmann H C
TH
Division of Psychology and Behavioral Immunobiology, Swiss Federal Institute of Technology Zurich, Zurich, Switzerland. krueger@ifv.gess.ethz.ch
Brink
Paul
P
Goebel
Marion U
MU
Schiffer
Boris
B
Schedlowski
Manfred
M
Hartmann
Uwe
U
Schneider
Udo
U
D000328:Adult; D000368:Aged; D000437:Alcoholism / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology*; D000728:Androgens / Q000097:blood* / Q000378:metabolism; D002220:Carbamazepine / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D003863:Depression / Q000175:diagnosis / Q000453:epidemiology / Q000523:psychology; D004958:Estradiol / Q000097:blood* / Q000378:metabolism; D000431:Ethanol / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood* / Q000378:metabolism; D007006:Hypogonadism / Q000139:chemically induced / Q000453:epidemiology; D008658:Inactivation, Metabolic; D007986:Luteinizing Hormone / Q000097:blood* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011388:Prolactin / Q000097:blood* / Q000378:metabolism; D012720:Severity of Illness Index; D013739:Testosterone / Q000097:blood* / Q000378:metabolism
D000728:Androgens; D002220:Carbamazepine; D000431:Ethanol; D013739:Testosterone; D004958:Estradiol; D011388:Prolactin; D007986:Luteinizing Hormone; D006854:Hydrocortisone